MDT

96.72

-0.11%↓

A

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

MDT

96.72

-0.11%↓

A

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

MDT

96.72

-0.11%↓

A

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

MDT

96.72

-0.11%↓

A

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

MDT

96.72

-0.11%↓

A

139.6

-0.01%↓

VEEV

222.15

-0.07%↓

HQY

85.02

0%↓

NEOG

9.23

-0.11%↓

Search

Maravai LifeSciences Holdings Inc (Class A)

Cerrado

3.92 0.26

Resumen

Variación precio

24h

Actual

Mínimo

3.92

Máximo

3.92

Métricas clave

By Trading Economics

Ingresos

44M

-26M

Ventas

-5.8M

42M

Margen de beneficio

-61.388

Empleados

550

EBITDA

44M

-22M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+8.42% upside

Dividendos

By Dow Jones

Próximas Ganancias

17 mar 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

367M

1.4B

Apertura anterior

3.66

Cierre anterior

3.92

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

19 ene 2026, 16:17 UTC

Adquisiciones, fusiones, absorciones

Zurich Insurance Makes $10 Billion Bid for U.K. Specialist Insurer Beazley -- Update

19 ene 2026, 23:50 UTC

Charlas de Mercado

Nikkei May Decline Amid Uncertainty Over U.S.-Europe Relations -- Market Talk

19 ene 2026, 23:42 UTC

Charlas de Mercado

Gold Edges Lower on Likely Technical Correction -- Market Talk

19 ene 2026, 22:29 UTC

Charlas de Mercado

China Infant Formula Market May Hold Up Despite Steep Drop in Births -- Market Talk

19 ene 2026, 22:29 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

19 ene 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

19 ene 2026, 21:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

19 ene 2026, 21:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

19 ene 2026, 17:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

19 ene 2026, 17:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

19 ene 2026, 17:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

19 ene 2026, 17:09 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

19 ene 2026, 17:09 UTC

Charlas de Mercado

Copper Rises in Spite of Softer Dollar, Trade Concerns -- Market Talk

19 ene 2026, 16:18 UTC

Charlas de Mercado

New Zealand Dollar Could Recover Against Swedish Krona -- Market Talk

19 ene 2026, 16:12 UTC

Charlas de Mercado

Norwegian Krone's Recent Gains Are Unlikely to Last -- Market Talk

19 ene 2026, 16:06 UTC

Adquisiciones, fusiones, absorciones

LVMH: Deal Completion Subject to Customary Closing Conditions and Expected to Close in Around Two Months

19 ene 2026, 16:04 UTC

Adquisiciones, fusiones, absorciones

LVMH: Both Parties Aim to Set Up Strategic Cooperation in the Retail Sector

19 ene 2026, 16:03 UTC

Adquisiciones, fusiones, absorciones

LVMH, CTG Duty-Free Also Entered Into a MoU

19 ene 2026, 16:02 UTC

Adquisiciones, fusiones, absorciones

LVMH: Subscription to Be Made Upon Completion of Transaction

19 ene 2026, 16:00 UTC

Adquisiciones, fusiones, absorciones

LVMH: Capital Increase by Subscribing to Newly Issued H-shares Listed in Hong Kong

19 ene 2026, 16:00 UTC

Charlas de Mercado

Term Premium on U.S. Treasurys Looks Too Low, Says Pictet AM -- Market Talk

19 ene 2026, 15:58 UTC

Adquisiciones, fusiones, absorciones

LVMH and the Miller Family Will Participate in a Capital Increase of CTG DutyFree

19 ene 2026, 15:57 UTC

Adquisiciones, fusiones, absorciones

LVMH: DFS Will Continue to Operate Its Other Luxury Travel Retail Operations Worldwide

19 ene 2026, 15:57 UTC

Adquisiciones, fusiones, absorciones

LVMH: Proceeds of Transaction Will Be Paid in Cash

19 ene 2026, 15:56 UTC

Adquisiciones, fusiones, absorciones

LVMH: CTG Duty-Free Will Run the Acquisition Through Its Subsidiary China Duty Free International Limited

19 ene 2026, 15:53 UTC

Adquisiciones, fusiones, absorciones

LVMH: Intangible Assets Include a Series of DFS Brands and IP for Exclusive Use in Greater China

19 ene 2026, 15:52 UTC

Adquisiciones, fusiones, absorciones

LVMH: CTG Duty-Free to Acquire the DFS Retail Stores in Hong Kong and Macau and Intangible Assets

19 ene 2026, 15:51 UTC

Adquisiciones, fusiones, absorciones

LVMH: DFS, CTG Duty-Free Reach Definitive Pact for CTG Duty-Free to Buy DFS' Travel Retail Unit in Hong Kong and Macau and Intangible Assets in Greater China

19 ene 2026, 15:39 UTC

Charlas de Mercado

Canadian Dollar's Underperformance Looks Overstretched -- Market Talk

19 ene 2026, 15:37 UTC

Charlas de Mercado

Bank of Canada Could Consider Cutting Rates if Underlying Inflation Slows Further -- Market Talk

Comparación entre iguales

Cambio de precio

Maravai LifeSciences Holdings Inc (Class A) Esperado

Precio Objetivo

By TipRanks

8.42% repunte

Estimación a 12 meses

Media 4.25 USD  8.42%

Máximo 4.5 USD

Mínimo 4 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Maravai LifeSciences Holdings Inc (Class A) Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

4 ratings

3

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

2.02 / 2.115Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

No Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat